Increased HIF1α expression significantly and inversely correlated with response to Epirubicin therapy [56] and was also shown to be an independent risk factor for resistance to aromatase inhibitor therapy [57] in 187 and 114 oestrogen receptor (ER) positive breast cancer patients, respectively. Here, HIF1A is linked to breast carcinoma.